1. Scrip
  2. >>Business
  3. >>Strategy

Timing is Everything; Tempo Raises Series A

 
• By Chris Morrison

Now that Tempo has raised a $12.1 million Series A round from Polaris, Venrock, Lux Capital and former Biogen Idec Inc. Chairman William Rastetter, PhD, the company is on the way toward solving a tricky drug delivery problem

Polaris Venture Partners has done quite well with what might broadly be called pharmaceutical technologies—businesses based on drug delivery and reformulation, rather than discovery. Their secret weapon: the Massachusetts Institute of Technology and, in particular, researcher Robert Langer, ScD.

Now they’re turning the crank again, though this time Langer is merely a key MIT connection (and a board member).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

More from Business

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.